Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2415:167-173.
doi: 10.1007/978-1-0716-1904-9_12.

Deploying Kinase Inhibitors to Study Pediatric Gliomas

Benjamin T Himes  1 , Liang Zhang  1 , David J Daniels  2
Affiliations

Deploying Kinase Inhibitors to Study Pediatric Gliomas

Benjamin T Himes et al. Methods Mol Biol. 2022.

Abstract

Pediatric midline gliomas are a uniformly fatal disease for which there is no cure. The location of these tumors makes surgical resection impossible, and so novel therapies are urgently needed to improve outcomes. The biology of these tumors is increasingly understood, with the histone H3K27M mutation playing a critical role in the pathogenesis of these tumors. Efforts to inhibit the growth of these tumors have also focused on inhibiting the Aurora kinase and Janus-associated kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in order to disrupt tumor proliferation. A number of small molecule inhibitors of these kinases have shown promise in early studies. Screening and preclinical assessment of such inhibitors requires a functional assay to assess the degree of kinase inhibition. We detail here a luciferase-based reporter assay for STAT3 transcriptional activity that we have employed frequently in order to assess the efficacy of kinase inhibitors in pediatric gliomas. The assay we describe is specific to STAT3, but the overall methodology is generalizable to other downstream targets of the kinase of interest.

Keywords: DIPG; H3K27M; Kinase inhibitors; Luciferase assay; Pediatric midline glioma; STAT3.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Clymer J, Kieran MW (2018) The integration of biology into the treatment of diffuse intrinsic pontine glioma: a review of the north American clinical trial perspective. Front Oncol 8:169. https://doi.org/10.3389/fonc.2018.00169 - DOI - PubMed - PMC
    1. MacDonald TJ, Aguilera D, Kramm CM (2011) Treatment of high-grade glioma in children and adolescents. Neuro-Oncology 13:1049–1058. https://doi.org/10.1093/neuonc/nor092 - DOI - PubMed - PMC
    1. Cartmill M, Punt J (1999) Diffuse brain stem glioma. A review of stereotactic biopsies. Childs Nerv Syst 15:235–237.; ; discussion 238. https://doi.org/10.1007/s003810050379 - DOI - PubMed
    1. Gupta N, Goumnerova LC, Manley P, Chi SN, Neuberg D, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, Gardner S, Karajannis MA, Harter D, Ayyanar K, Gump W, Bowers DC, Weprin B, MacDonald TJ, Aguilera D, Brahma B, Robison NJ, Kiehna E, Krieger M, Sandler E, Aldana P, Khatib Z, Ragheb J, Bhatia S, Mueller S, Banerjee A, Bredlau AL, Gururangan S, Fuchs H, Cohen KJ, Jallo G, Dorris K, Handler M, Comito M, Dias M, Nazemi K, Baird L, Murray J, Lindeman N, Hornick JL, Malkin H, Sinai C, Greenspan L, Wright KD, Prados M, Bandopadhayay P, Ligon KL, Kieran MW (2018) Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology 20:1547–1555. https://doi.org/10.1093/neuonc/noy070 - DOI - PubMed - PMC
    1. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, Grill J, Boddaert N, Di Rocco F, Zerah M, Sainte-Rose C (2007) Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 107:1–4. https://doi.org/10.3171/PED-07/07/001 - DOI - PubMed

LinkOut - more resources